Copyright Reports & Markets. All rights reserved.

Glucose Monitoring Global Market - Forecast to 2025

Request for Sample of this report
Buy now

1 EXECUTIVE SUMMARY 27

    2 INTRODUCTION 33

    • 2.1 KEY TAKEAWAYS 33
    • 2.2 REPORT DESCRIPTION 34
    • 2.3 MARKETS COVERED 36
    • 2.4 STAKEHOLDERS 37
    • 2.5 RESEARCH METHODOLOGY 38
      • 2.5.1 MARKET SIZE ESTIMATION 40
      • 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 42
      • 2.5.3 SECONDARY SOURCES 43
      • 2.5.4 PRIMARY SOURCES 44
      • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 44
      • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 45
      • 2.5.7 ASSUMPTIONS 45

    3 MARKET ANALYSIS 47

    • 3.1 INTRODUCTION 47
    • 3.2 MARKET SEGMENTATION 48
    • 3.3 FACTORS INFLUENCING MARKET 50
      • 3.3.1 DRIVERS AND OPPORTUNITIES 51
        • 3.3.1.1 The global rise in the prevalence and incidence of diabetes 51
        • 3.3.1.2 Technological advancements in glucose monitoring devices 52
        • 3.3.1.3 Increasing demand for less invasive devices or point of care 53
        • 3.3.1.4 Increasing R & D investments 53
      • 3.3.2 RESTRAINS AND THREATS 54
        • 3.3.2.1 Availability of alternative treatment 54
        • 3.3.2.2 High cost associated with the products 55
        • 3.3.2.3 Inadequate reimbursement 55
        • 3.3.2.4 Product recalls 57
        • 3.3.2.5 Strict regulation of glucose monitoring devices by regulatory organizations

      like the FDA and others. 57

      • 3.4 REGULATORY AFFAIRS 59
        • 3.4.1 U.S. 59
        • 3.4.2 EUROPE 62
        • 3.4.3 CHINA 63
        • 3.4.4 INDIA 64
        • 3.4.5 JAPAN 65
      • 3.5 REIMBURSEMENT SCENARIO 66
      • 3.6 PATENT ANALYSIS 72
      • 3.7 TECHNOLOGY ADVANCEMENTS 74
        • 3.7.1 ARTIFICIAL INTELLIGENCE AND RADAR TECHNOLOGY 74
        • 3.7.2 NON-INVASIVE CONTINUOUS GLUCOSE MONITORING WEARABLE 74
        • 3.7.3 TEAR GLUCOSE MONITORING TECHNOLOGY 74
        • 3.7.4 SALIVA BASED BIOSENSORS 75
        • 3.7.5 MICRONEEDLE PATCH 75
        • 3.7.6 PHOTOTHERMAL DETECTION OF GLUCOSE LEVELS 75
      • 3.8 PRODUCT LAUNCHES AND APPROVALS 76
      • 3.9 FUNDING SCENARIO 92
      • 3.10 GLUCOSE MONITORING - DEALS 94
      • 3.11 CLINICAL TRIAL DATA 96
      • 3.12 PORTER’S FIVE FORCE ANALYSIS 100
        • 3.12.1 THREAT OF NEW ENTRANTS 101
        • 3.12.2 THREAT OF SUBSTITUTES 102
        • 3.12.3 BARGAINING POWER OF SUPPLIERS 102
        • 3.12.4 BARGAINING POWER OF BUYERS 103
        • 3.12.5 RIVALRY AMONG EXISTING COMPETITORS 104
      • 3.13 SUPPLY CHAIN ANALYSIS 105
      • 3.14 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 109
        • 3.14.1 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS 109
        • 3.14.2 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE

      ANALYSIS 112

      • 3.14.3 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET

    SHARE ANALYSIS 115

      4 GLUCOSE MONITORING GLOBAL MARKET, BY PRODUCTS 117

      • 4.1 INTRODUCTION 117
      • 4.2 INVASIVE GLUCOSE MONITORING 120
        • 4.2.1 SELF GLUCOSE MONITORING 124
          • 4.2.1.1 Blood glucose meter 130
          • 4.2.1.2 Blood glucose testing strips 134
          • 4.2.1.3 Lancets 137
          • 4.2.1.4 Others 140
        • 4.2.2 CONTINUOUS GLUCOSE MONITORING 143
          • 4.2.2.1 Glucose Sensors 150
          • 4.2.2.2 Transmitters and Receivers 153
      • 4.3 NON-INVASIVE GLUCOSE MONITORING 156
      • 4.4 LAB BASED GLUCOSE MONITORING 169

      5 GLUCOSE MONITORING GLOBAL MARKET, BY SAMPLE SOURCE 173

      • 5.1 INTRODUCTION 173
      • 5.2 BLOOD-BASED GLUCOSE MONITORING 176
      • 5.3 URINE BASED GLUCOSE MONITORING 179
      • 5.4 OTHER SOURCES BASED GLUCOSE MONITORING 182

      6 GLUCOSE MONITORING GLOBAL MARKET, BY END-USERS 186

      • 6.1 INTRODUCTION 186
      • 6.2 HOSPITALS 189
      • 6.3 HOME CARE 195
      • 6.4 PRIVATE CLINICS 200
      • 6.5 AMBULATORY SETTINGS 203

      7 REGIONAL ANALYSIS 206

      • 7.1 INTRODUCTION 206
      • 7.2 NORTH AMERICA 209
        • 7.2.1 U.S. 223
        • 7.2.2 REST OF NORTH AMERICA 227
      • 7.3 EUROPE 231
        • 7.3.1 GERMANY 244
        • 7.3.2 ITALY 248
        • 7.3.3 FRANCE 251
        • 7.3.4 REST OF EUROPE 254
      • 7.4 ASIA - PACIFIC 257
        • 7.4.1 JAPAN 271
        • 7.4.2 CHINA 274
        • 7.4.3 INDIA 277
        • 7.4.4 REST OF ASIA-PACIFIC 280
      • 7.5 REST OF THE WORLD 284
        • 7.5.1 BRAZIL 298
        • 7.5.2 MIDDLE EAST & OTHERS 301
        • 7.5.3 REST OF LATIN AMERICA 304

      8 COMPETITIVE LANDSCAPE 307

      • 8.1 INTRODUCTION 307
      • 8.2 NEW PRODUCT LAUNCHES 309
      • 8.3 COLLABORATION & PARTNERSHIPS 310
      • 8.4 OTHER DEVELOPMENTS 311

      9 MAJOR COMPANIES 312

      • 9.1 ABBOTT LABORATORIES, INC 312
        • 9.1.1 OVERVIEW 312
        • 9.1.2 FINANCIALS 313
        • 9.1.3 PRODUCT PORTFOLIO 316
        • 9.1.4 KEY DEVELOPMENTS 317
        • 9.1.5 BUSINESS STRATEGY 318
        • 9.1.6 SWOT ANALYSIS 319
      • 9.2 ARKRAY, INC. 320
        • 9.2.1 OVERVIEW 320
        • 9.2.2 FINANCIALS 320
        • 9.2.3 PRODUCT PORTFOLIO 321
        • 9.2.4 KEY DEVELOPMENTS 322
        • 9.2.5 BUSINESS STRATEGY 322
        • 9.2.6 SWOT ANALYSIS 323
      • 9.3 ASCENSIA DIABETES CARE HOLDINGS AG. 324
        • 9.3.1 OVERVIEW 324
        • 9.3.2 FINANCIALS 324
        • 9.3.3 PRODUCT PORTFOLIO 325
        • 9.3.4 KEY DEVELOPMENTS 326
        • 9.3.5 BUSINESS STRATEGY 326
        • 9.3.6 SWOT ANALYSIS 327
      • 9.4 B.BRAUN MELSUNGEN AG 328
        • 9.4.1 OVERVIEW 328
        • 9.4.2 FINANCIALS 329
        • 9.4.3 PRODUCT PORTFOLIO 332
        • 9.4.4 KEY DEVELOPMENTS 333
        • 9.4.5 BUSINESS STRATEGY 333
        • 9.4.6 SWOT ANALYSIS 334
      • 9.5 BIO-RAD LABORATORIES 335
        • 9.5.1 OVERVIEW 335
        • 9.5.2 FINANCIALS 336
        • 9.5.3 PRODUCT PORTFOLIO 339
        • 9.5.4 KEY DEVELOPMENTS 340
        • 9.5.5 BUSINESS STRATEGY 340
        • 9.5.6 SWOT ANALYSIS 341
      • 9.6 DEXCOM, INC. 342
        • 9.6.1 OVERVIEW 342
        • 9.6.2 FINANCIALS 343
        • 9.6.3 PRODUCT PORTFOLIO 344
        • 9.6.4 KEY DEVELOPMENTS 345
        • 9.6.5 BUSINESS STRATEGY 345
        • 9.6.6 SWOT ANALYSIS 346
      • 9.7 LIFESCAN (JOHNSON & JOHNSON) 347
        • 9.7.1 OVERVIEW 347
        • 9.7.2 FINANCIALS 348
        • 9.7.3 PRODUCT PORTFOLIO 352
        • 9.7.4 KEY DEVELOPMENTS 352
        • 9.7.5 BUSINESS STRATEGY 353
        • 9.7.6 SWOT ANALYSIS 354
      • 9.8 MEDTRONIC, PLC 355
        • 9.8.1 OVERVIEW 355
        • 9.8.2 FINANCIALS 356
        • 9.8.3 PRODUCT PORTFOLIO 359
        • 9.8.4 KEY DEVELOPMENTS 360
        • 9.8.5 BUSINESS STRATEGY 360
        • 9.8.6 SWOT ANALYSIS 361
      • 9.9 SINOCARE INC. 362
        • 9.9.1 OVERVIEW 362
        • 9.9.2 FINANCIALS 363
        • 9.9.3 PRODUCT PORTFOLIO 363
        • 9.9.4 KEY DEVELOPMENTS 363
        • 9.9.5 BUSINESS STRATEGY 364
        • 9.9.6 SWOT ANALYSIS 365
      • 9.10 ROCHE HOLDINGS AG 366
        • 9.10.1 OVERVIEW 366
        • 9.10.2 FINANCIALS 367
        • 9.10.3 PRODUCT PORTFOLIO 371
        • 9.10.4 KEY DEVELOPMENTS 373
        • 9.10.5 BUSINESS STRATEGY 373

      Glucose Monitoring consists of products that are essential for patients suffering from diabetes. With the projected rise in the aged population and awareness about such conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the Glucose Monitoring global market is expected to grow at single digit CAGR to reach $12,897.0 million by 2025. Factors driving the Glucose Monitoring market are a global rise in the prevalence and incidence of diabetes, continuous technological advancement, increasing demand for less invasive products, and an increase in R&D investments are driving the market growth. Increase in obesity population due to lifestyle changes, increase in urbanization, untapped markets like the Middle East, Africa shows that glucose monitoring market has vast opportunities in the coming years. Frequent product recalls i.e. glucose testing strips due to manufacturing defects or supply of expired test strips and less product differentiation among the self blood glucose monitors are the factors that are restraining the market growth. The limited reimbursement facilities and alternative treatments that include cell-based assays, biomarkers identification and artificial pancreas and high cost associated with Continuous Glucose Monitoring (CGM) are threats for the market growth.
      Glucose Monitoring global market is classified based on products, sample type, end-users and geography. The products segment is divided into three segments i.e., Invasive, Non-Invasive and lab-based glucose monitoring products. The Invasive glucose monitoring products segment accounted the largest share in 2018 and is projected to grow at a low single digit CAGR from 2018 to 2025 due to technological advancements, easy use, patient-friendly, etc. Invasive products are classified into Self glucose monitoring and continuous glucose products. The self glucose monitoring segment accounted for the largest share in 2018 due to the development of minimally invasive products. The Self glucose monitoring products are further classified into blood glucose monitors, blood glucose test strips, lancets and others. The blood glucose testing strips segment accounted for the largest share in 2018 due development of no coding strips. The continuous glucose monitoring market includes sensors/receiver and transmitter. The continuous glucose market includes products sensors/receiver and transmitter. Continuous glucose segment is the fastest growing segment and is projected to grow at a strong double digit CAGR from 2018 to 2025.
      Based on sample type the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2018 due to the accuracy of results. Other source based glucose monitoring segment is fastest growing segment and is projected to grow exponentially from 2018 to 2025 due to increases R&D investment, many products is CE approved and expected launch very soon in the market.
      Based on end users the market is segmented into hospitals, private clinics, home care and ambulatory settings. Among end-users, home care segment accounted for the largest share in 2018 and is projected to grow at a low single digit CAGR from 2018 to 2025 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels.
      Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Others), Asia-Pacific (Japan, China, India and Others) and Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the highest market share followed by Europe. The steep rise in aging population, advancement in technology, awareness of people about treatment options and favorable government policies are driving factors of glucose monitoring market. However, Asian countries especially India and China are the fastest growing regions with its growing demand for glucose monitoring products.
      Major players in Glucose monitoring market include Abbott Laboratories (U.S.), Roche (Switzerland), LifeScan (U.S.), Dexcom (U.S.), Medtronic, Inc. (Ireland), Ascensia (Switzerland), Arkray (Japan), Sinocare (China), B. Braun Melsungen AG (Germany), Bio-Rad (U.S.), etc.
      The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
      • North America
      o U.S.
      o Others
      • Europe
      o Germany
      o Italy
      o France
      o Others
      • Asia-Pacific
      o Japan
      o China
      o India
      o Others
      • Rest of the World (RoW)
      o Brazil
      o Rest of Latin America
      o Middle-East (Middle East & Others)

      Buy now